SCHEMBL48228

SCHEMBL48228

O=Cc1c[nH]c(=O)[nH]c1=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPYD Q12882 5/20 0.65
MAPT P10636 3/20 0.48
GAA P10253 3/20 0.48
ALDH1A1 P00352 2/20 0.48
ATAD2 Q6PL18 1/20 0.48
LMNA P02545 1/20 0.48
CYP19A1 P11511 1/20 0.48
TSHR P16473 1/20 0.48
THPO P40225 1/20 0.48
MTOR P42345 1/20 0.48
HTT P42858 1/20 0.48
HBB P68871 1/20 0.48
PMP22 Q01453 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
KDM4C Q9H3R0 1/20 0.38
CYP2A6 P11509 1/20 0.38
IMPDH2 P12268 1/20 0.38
GRIA1 P42261 1/20 0.36
GRIA2 P42262 1/20 0.36
GRIA3 P42263 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10696940 1.00 DPYD (0.65) DPYDMAPTGAAALDH1A1ATAD2
SCHEMBL1916591 0.79 DPYD (0.63) DPYDMAPTGAAALDH1A1ATAD2
SCHEMBL1228163 0.79 DPYD (0.63) DPYDMAPTGAAALDH1A1ATAD2
SCHEMBL170251 0.79 DPYD (1.00) DPYDMAPTGAAALDH1A1ATAD2
SCHEMBL23622048 0.77 DPYD (0.45) DPYDMAPTGAAALDH1A1ATAD2
SCHEMBL21345242 0.77 KDM3B (0.47) DPYDMAPTGAAALDH1A1CYP2A6
SCHEMBL6374591 0.76 DPYD (0.59) DPYDMAPTGAAALDH1A1ATAD2
SCHEMBL6374582 0.76 DPYD (0.59) DPYDMAPTGAAALDH1A1ATAD2
SCHEMBL15798473 0.76 DPYD (0.62) DPYDMAPTGAAALDH1A1ATAD2
SCHEMBL65892 0.76 DPYD (0.62) DPYDMAPTGAAALDH1A1ATAD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 863 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106497-A2 FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) 2026-05-21 WO claimed
US-12630851-B2 Polynucleotide modification methods OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-05-19 US claimed
US-20250369027-A1 SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS TWIST BIOSCIENCE CORP (US) 2025-12-04 US claimed
US-20250327068-A1 Method for Generation of a Nucleic Acid Library MILTENYI BIOTEC BV & CO KG (DE) 2025-10-23 US claimed
EP-4569132-A2 METHOD, KIT AND SYSTEM FOR END LABELING OF NUCLEIC ACIDS Chen, Cheng-Yao (TW) 2025-06-18 EP claimed
WO-2025111452-A2 CHEMICAL MODIFICATIONS IN PEgRNA and ngRNAs PRIME MEDICINE, INC. (US) 2025-05-30 WO claimed
CN-120077136-A SiRNA and drug for inhibiting Amyloid Precursor Protein (APP) gene expression and application thereof 广州必贝特医药股份有限公司 2025-05-30 CN claimed
WO-2025111430-A1 CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL PRIME MEDICINE, INC. (US) 2025-05-30 WO claimed
CN-119948172-A Methods, kits and systems for nucleic acid end labeling 陈呈尧 2025-05-06 CN claimed
CN-119286094-B Graphite tailing/polyethylene composite material and preparation method thereof 黑龙江省朴澍科技有限责任公司 2025-05-06 CN claimed
EP-1281757-A1 Method for the production of nucleic acids consisting of stochastically combined parts of source nucleic acids Direvo Biotech AG (DE) 2003-02-05 EP claimed
WO-2002083123-A1 AURONES AS TELOMERASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2002-10-24 WO claimed
US-6369237-B1 ENZYME INHIBITORS OF DNA GLYCOLASE PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2002-04-09 US claimed
US-20020026053-A1 Novel 3-(substituted) -2- indolinones compounds and use thereof as inhibitors of protein kinase activity TANG PENG CHO (US) 2002-02-28 US claimed
US-20010007033-A1 Novel 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity SUGEN, INC. 2001-07-05 US claimed
WO-1999050447-A1 METHOD AND NUCLEIC ACID COMPOUND FOR BREAKING DOWN NUCLEIC ACID MOLECULES SYNTHESIZED $i(IN VITRO) MIRA DIAGNOSTIKA GMBH (DE) 1999-10-07 WO claimed
WO-1998039334-A9 DNA GLYCOSYLASE INHIBITORS, AND USES RELATED THERETO 1999-02-18 WO claimed
WO-1998039334-A1 DNA GLYCOSYLASE INHIBITORS, AND USES RELATED THERETO PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1998-09-11 WO claimed
WO-1993017651-A2 ANTIVIRAL NUCLEOSIDE ANALOGUES, THEIR PRODUCTION AND USE Max-Delbrück-Centrum für Molekulare Medizin (DE) 1993-09-16 WO claimed
US-5118800-A Oligonucleotides possessing a primary amino group in the terminal nucleotide CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1992-06-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020026053-A1 Novel 3-(substituted) -2- indolinones compounds and use thereof as inhibitors of protein kinase activity MAP3K20, SBK3, MAP4K2 DPYD 807/4885MAPT 3371/4885GAA 2413/4885
US-12630851-B2 Polynucleotide modification methods PNP, NT5C3B, UNG DPYD 43/4885MAPT 3328/4885GAA 1181/4885
US-20010007033-A1 Novel 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity SBK3, MAP4K2, MAP3K20 DPYD 797/4885MAPT 3376/4885GAA 2450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.